Traws Pharma, Inc. Net Income Loss

• Traws Pharma, Inc. showed a decrease of -778.8% in Net Income Loss from 2023 to 2024.
• This data is from Traws Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
• XBRL data for this metric is available from 2011 to 2024 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2012: -$10.80 million | Q2 2012: -$7.42 million | Q3 2012: -$1.44 million | Q4 2012: -$10.26 million | Q1 2013: -$14.85 million | Q2 2013: -$12.56 million | Q3 2013: -$20.52 million | Q4 2013: -$14.62 million | Q1 2014: -$18.68 million | Q2 2014: -$16.75 million | Q3 2014: -$14.88 million | Q1 2015: -$12.34 million | Q2 2015: -$8.96 million | Q3 2015: -$5.87 million | Q1 2016: -$7.24 million | Q2 2016: -$5.38 million | Q3 2016: -$1.60 million | Q1 2017: -$8.34 million | Q2 2017: -$2.58 million | Q3 2017: -$6.96 million | Q1 2018: -$5.09 million | Q2 2018: -$4.48 million | Q3 2018: -$5.35 million | Q1 2019: -$7.60 million | Q2 2019: -$3.56 million | Q3 2019: -$4.60 million | Q2 2023: -$4.25 million | Q3 2023: -$4.74 million | Q1 2024: -$4.98 million | Q2 2024: -$123.14 million | Q3 2024: -$8.48 million | Q1 2025: $21.49 million | Q2 2025: -$915.0 thousand | Q3 2025: -$3.96 million.
• Over the full 11 years of available data (2011 to 2024), Traws Pharma, Inc.'s Net Income Loss has declined by 533.3%.
• Historical annual values: Fiscal year 2024: -$166.52 million | Fiscal year 2023: -$18.95 million | Fiscal year 2019: -$21.50 million | Fiscal year 2018: -$20.57 million | Fiscal year 2017: -$24.09 million | Fiscal year 2016: -$19.67 million | Fiscal year 2015: -$23.98 million | Fiscal year 2014: -$63.68 million | Fiscal year 2013: -$62.54 million | Fiscal year 2012: -$29.91 million | Fiscal year 2011: -$26.29 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026